Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer
Dan Nicolson, Director of Biopharma Business Development at Personalis, Inc., shared a post on X:
“Lead Author, Dr. Paolo Tarantino of Dana-Farber Cancer Institute reviews – Despite being clearly prognostic among patients with Residual Disease, ctDNA detection still harbors complexities that warrant fine-tuning before implementation in clinical practice, with the most relevant one being the wide differences in sensitivity of the assays.
In this setting, strategies are being pursued to optimize sensitivity through the tracking of large numbers of individualized tumor genetic variants and the development of priming agents that transiently reduce the clearance of ctDNA, improving the sensitivity of detection for small tumors.
These strategies may hopefully reduce the risk of false negative MRD findings, enabling better prognostication and potentially improving treatment tailoring.
Authors: Paolo Tarantino, Gabriel Hortobagyi, Sara M. Tolaney, Elizabeth A. Mittendorf.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023